What is the treatment for persistent Methicillin-Sensitive Staphylococcus aureus (MSSA) bacteremia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Cefazolin is the preferred treatment for persistent Methicillin-Sensitive Staphylococcus aureus (MSSA) bacteremia.

Key Considerations

  • The choice of antibiotic therapy for Staphylococcus aureus bacteremia (SAB) depends on whether the isolate is methicillin-susceptible or -resistant, with beta-lactams showing superior outcomes for MSSA bloodstream infections compared to vancomycin 1.
  • Cefazolin is a suitable option for MSSA bacteremia, despite concerns about the cefazolin inoculum effect (CzIE), which may decrease its efficacy in some isolates.
  • Recent observational data suggest similar efficacy, or even a trend towards superiority of cefazolin over anti-staphylococcal penicillins (ASPs), such as cloxacillin 1.
  • The preferable safety profile of cefazolin compared to ASPs, along with large-scale observational data supporting its efficacy, make it a comfortable choice for most patients with MSSA bacteremia 1.

Treatment Approach

  • Beta-lactam therapy, such as cefazolin, should be considered as the primary treatment for MSSA bacteremia.
  • In areas with high MRSA prevalence, an empiric combination approach (e.g., vancomycin or daptomycin and a beta-lactam) may be considered to provide optimal upfront therapy for both MSSA and MRSA, but this approach is still debated 1.

From the Research

Treatment Options for Persistent Methicillin-Sensitive Staphylococcus aureus (MSSA) Bacteremia

The treatment for persistent MSSA bacteremia is not well-established, but several options are available:

  • Modification of antimicrobial therapy, in conjunction with source control and infectious diseases consultation, may be necessary to sterilize blood cultures in patients with persistent MSSA bacteremia 2
  • Dual β-lactam regimens may be considered for persistent MSSA bacteremia, although data are limited to case reports and case series 2
  • Cefazolin and cloxacillin are commonly used antibiotics for the treatment of MSSA bacteremia, and treatment with cefazolin is not significantly different from treatment with cloxacillin 3
  • Other beta-lactams, including second and third generation cephalosporins, might be associated with higher mortality 3

Considerations for Treatment

When selecting a treatment regimen for persistent MSSA bacteremia, the following factors should be considered:

  • Recent exposure to antibiotics
  • Source control
  • Available synergy and clinical data
  • The potential for combination therapy, such as the use of multiple antibiotics together 4, 5

Limitations of Current Evidence

There is limited guidance on the best approach for managing patients with persistent MSSA bacteremia, and further research is needed to establish a preferred treatment regimen 2, 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2011

Research

Fosfomycin as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia: A case series and review of the literature.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.